Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
  • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
  • A61K47/6817—Toxins
  • A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/64—Cyclic peptides containing only normal peptide links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide

Definitions

• the present disclosure provides derivatives of amanitin conjugated to a targeting antibody to form an ADC (antibody drug conjugate).
• the amatoxins are rigid bicyclic peptides having eight amino acid units. These compounds are isolated from a variety of mushroom species (e.g., Amanita phalloides (also known as green death cap mushroom), Galerina marginata, Lepiota brunneo-incamata) or are prepared synthetically. Different mushroom species contain varying amounts of different Amatoxin family members. A member of this family, alpha- amanitin, is known to be an inhibitor of eukaryotic RNA polymerase II (EC2.7.7.6) and to a lesser degree, RNA polymerase III, thereby inhibiting transcription and protein biosynthesis. Wieland (1983) Int. J. Pept. Protein Res. 22(3):257-276. Alpha- amanitin binds non-covalently to RNA polymerase II and dissociates slowly, making enzyme recovery unlikely. Prolonged inhibition of transcription is thought to induce cellular apoptosis.
• Amanita phalloides also known as green
• amatoxins include:
• ADCs antibody-drug conjugates
• Pinchera et al. (eds.), pp. 475-506. This type of delivery mechanism helps to minimize toxicity to normal cells that may occur from systemic administration of unconjugated drug agents.
• the toxins may cause their cytotoxic and cytostatic effects through a variety of mechanisms including tubulin binding, DNA binding, or topoisomerase inhibition. Both polyclonal antibodies and monoclonal antibodies have been reported as useful in these strategies. Rowland et al. (1986) Cancer Immunol. Immunother. 21: 183-87.
• Toxins used in antibody-toxin conjugates include radioisotopes, bacterial toxins such as diphtheria toxin, plant toxins such as ricin, fungal toxins such as amatoxins (WO2010/115629, W02012/041504 or WO2012/119787), and small molecule toxins such as geldanamycin (Mandler et al. (2000) J. Natl. Cancer Inst. 92(19): 1573- 1581; Mandler et al. (2000) Bioorg. Med. Chem. Lett. 10: 1025-1028; Mandler et al. (2002) Bioconjugate Chem. 13:786-791), maytansinoids (EP 1391213; Liu et al. (1996) Proc.
• ZEVALIN® ibritumomab tiuxetan, Biogen/Idec
• an antibody- radioisotope conjugate composed of a murine IgGl kappa monoclonal antibody (directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes) connected with an 11 lln or 90Y radioisotope via a thiourea linker-chelator.
• ADCs antibody-drug conjugates
• cytotoxic or cytostatic agents including drugs that kill or inhibit tumor cells
• ADCs antibody-drug conjugates
• This type of delivery mechanism helps to minimize toxicity to normal cells that may occur from systemic administration of unconjugated drug agents.
• the toxins may cause their cytotoxic and cytostatic effects through a variety of mechanisms including tubulin binding.
• the present disclosure provides improved amatoxin derivatives used in an ADC
• antibody drug conjugate structure. More specifically, the present disclosure provides an antibody drug conjugate (ADC) having the structure of Formula I
• Ab is a monoclonal antibody
• L 1 - L 2 is a linker selected from the group consisting of
• L - X is a linker having structure of wherein R 4 is hydrogen, C 1-6 alkyl, -(CH 2 CH 2 0) m -, or the combination thereof, and m is an integer from 1-24;
• D is a drug moiety active agent derived from amatoxin and selected from the group consisting of alpha- amanit in, beta-amanitin, gamma-amanitin, and epsilon-amanitin having the s
• n an nteger rom - ;
• L is a linker selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, -(CH 2 ) P -, -(CH 2 CH 2 0) m -, -C(0)NH-, -NHC(O)-, PAB (p- aminobenzyl), Val-Cit-PAB, Val-Ala-PAB, Ala-Ala-Asn-PAB, -R 6 OC(0)NR 5 -, -R 8 -S-S-R 7 , and combinations thereof, wherein R 5 is selected from the group consisting of hydrogen, C 1-6 alkyl, -(CH 2 ) P -, - (CH 2 CH 2 0) m -, and combinations thereof;
• R 6 is selected from the group consisting of an amino acid, peptide consisting of up to 10 aminoacids, Ci -6 alkyl, -(CH 2 ) P -, -(CH 2 CH 2 0) m -, -C(0)NH-, -NHC(O)-, PAB, Val-Cit- PAB, Val-Ala-PAB, Ala-Ala-Asn-PAB , and combinations thereof;
• R 7 is C 2 -6 alkylene, or -(CH 2 CH 2 0) m -;
• Rg is selected from the group consisting of an amino acid, peptide consisting of up to 10 aminoacids, Ci-6 alkyl, Ci-6 alkylene, substituted Ci-6 alkylene, -C(0)NH-, -C(0)-NH- CHR 9 -CR10R11-, -NHC(0)-CHR 9 -CRioRii-, -(CH 2 CH 2 0) m -, PAB, Val-Cit-PAB, Val-Ala- PAB, Ala-Ala-Asn-PAB , and combinations thereof;
• R9 is selected from the group consisting of hydrogen, Ci-6 alkyl, Ci-6 alkylene, -(CH 2 CH 2 0) m -, -C(0)NH-, -NHC(O)-, -C(0)NH-(CH 2 )p-S0 3 H, C(0)NH-(CH 2 )p- C0 2 H, -NHC(0)-(CH 2 )p-S0 3 H, -NHC(0)-(CH 2 )p-C0 2 H and combinations thereof;
• Rio and Rn are each independently selected from the group consisting of hydrogen, Ci-6 alkyl, and combinations thereof;
• n is an integer from 1-24;
• p is an integer from 1-6.
• L in the compounds having the structure of Formula I is a linker selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, -(CH 2 ) P -, -(CH 2 CH 2 0) m -, -C(0)NH-, -NHC(O)-, PAB (p-aminobenzyl), -Val-Cit- PAB-, -Val-Ala-PAB-, -Ala-Ala-Asn- ⁇ -, -R 6 OC(0)NR 5 -, -Rg-S-S-R 7 , and combinations thereof,
• R5 is selected from the group consisting of hydrogen, Ci-6 alkyl, -(CH 2 ) P -, - (CH 2 CH 2 0) m -, and combinations thereof;
• R 6 is selected from the group consisting of an amino acid, peptide consisting of up to 10 aminoacids, Ci -6 alkyl, -(CH 2 ) P -, -(CH 2 CH 2 0) m -, -C(0)NH-, -NHC(O)-, PAB, -Val-Cit- PAB-, -Val-Ala-PAB-, -Ala-Ala-Asn- ⁇ - , and combinations thereof;
• R 7 is C 2 -6 alkylene, or -(CH 2 CH 2 0) m -;
• Rg is selected from the group consisting of an amino acid, peptide consisting of up to 10 aminoacids, Ci-6 alkyl, Ci-6 alkylene, substituted Ci-6 alkylene, -C(0)NH-, -C(0)-NH- CHR 9 -CR10R11-, -NHC(0)-CHR 9 -CRioRii-, -(CH 2 CH 2 0) m -, PAB, -Val-Cit- ⁇ -, -Val-Ala- PAB-, -Ala-Ala-Asn- ⁇ - , and combinations thereof;
• R9 is selected from the group consisting of hydrogen, Ci-6 alkyl, Ci-6 alkylene, -(CH 2 CH 2 0) m -, -C(0)NH-, -NHC(O)-, -C(0)NH-(CH 2 )p-S0 3 H, C(0)NH-(CH 2 )p- C0 2 H, -NHC(0)-(CH 2 )p-S0 3 H, -NHC(0)-(CH 2 )p-C0 2 H and combinations thereof;
• Rio and Rn are each independently selected from the group consisting of hydrogen, Ci-6 alkyl, and combinations thereof;
• n is an integer from 1-24;
• p is an integer from 1-6, wherein the remaining values are as described above for Formula I.
• L in the compounds having the structure of Formula I is a linker selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, -(CH 2 ) P -, -(CH 2 CH 2 0) m -, -C(0)NH-, -NH(4-phenyl)CH 2 0-, -Val-Cit-NH(4- phenyl)CH 2 0-, -Val-Ala-NH(4-phenyl)CH 2 0-, -Ala-Ala-Asn-NH(4-phenyl)CH 2 0-, - R60C(0)NR 5 -, -R 8 -S-S-R 7 -, and combinations thereof,
• R 5 is selected from the group consisting of hydrogen, Ci-6 alkyl, -(CH 2 ) P -, - (CH 2 CH 2 0) m -, and combinations thereof;
• R 6 is selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, Ci -6 alkyl, -(CH 2 ) P -, -(CH 2 CH 2 0) m -, -C(0)NH-, -NH(4-phenyl)CH 2 -, -Val- Cit-NH(4-phenyl)CH 2 -, -Val-Ala-NH(4-phenyl)CH 2 -, -Ala-Ala-Asn-NH(4-phenyl)CH 2 - , and combinations thereof;
• R 7 is C 2-6 alkylene, or -(CH 2 CH 2 0) m -;
• R 8 is selected from the group consisting of an amino acid, peptide consisting of up to 10 amino acids, Ci-6 alkyl, Ci-6 alkylene, substituted Ci-6 alkylene, -C(0)-NH-CHRci- CR10R11-, -NHC(0)-CHR 9 -CRioRii-, -(CH 2 CH 2 0) m -, -PAB-, -Val-Cit-NH(4-phenyl)CH 2 -, - Val-Ala-NH(4-phenyl)CH 2 -, -Ala-Ala-Asn-NH(4-phenyl)CH 2 - , and combinations thereof; wherein R9 is selected from the group consisting of hydrogen, Ci-6 alkyl, Ci-6 alkylene, -(CH 2 CH 2 0) m -, -C(0)NH-, -NHC(O)-, -C(0)NH-(CH 2 )p-S0 3 H, -C(0)
• Rio and Rn are each independently selected from the group consisting of hydrogen, Ci-6 alkyl, and combinations thereof; wherein -R 6 0C(0)NRs- is connected to L 1 through R 6 ;
• n is an integer from 1-24;
• p is an integer from 1-6, wherein the remaining values are as described above for Formula I.
• D has a structure of Formula II:
• Ri is NH 2 or OR 2 , wherein R 2 is H, or Ci-Cio alkyl, and wherein R 3 is H or OH.
• the disclosed ADC is selected from the group consisting of:
• Figure 1 shows a comparison of in vitro cytotoxicity of ADC A (22) and ADC B on four cell lines, one cell line in each of the four panels of Figure 1.
• Figure 2 shows in vitro cytotoxity of ADC24 (see Table 2).
• Figure 3 shows in vitro cytotoxicity of ADC 22 (see Table 2) on various cell lines.
• Figure 4 shows in vitro cytotoxicity of ADC 26 on various cell lines.
• Figure 5 shows in vitro cytotoxicity of ADC 27 on various cell lines.
• Figure 6 shows in vitro cytotoxicity of ADC 25 on various cell lines.
• Figure 7 shows in vitro cytotoxicity of ADC 29 on various cell lines.
• Figure 8 shows efficacy of cMet/EGFR-22, cMet-22 and Nimo-22 in H292 xenograft: cMet/EGFR-22 and Nimo-22 significantly inhibited H292 tumor growth compared to PBS control group.
• Figure 9 shows a tumor size comparison for compound 29.
• cMet/EFFR-22 and Nimo- 22 significantly reduced tumor size/Weight compared to PBS Control group.
• Nimo-22 had some complete tumor regression (4 out of 7 mice was tumor free).
• Figure 10 shows no significant cMet/EGFR-22, cMet-22, Nimo-22 treatment-related body weight loss was observed.
• Figure 11 shows cMet/EGFR-23, cMet-23 and Nimo-23 treated groups showed significantly reduced tumor volume compared to PBS Control group.
• Figure 12 shows cMet/EGFR-23, cMet-23 and Nimo-23 treated groups showed significantly reduced tumor weight compared to PBS Control group.
• Figure 13 shows that no body weight loss was observed in cMet-23, cMet/EGFR-23, and Nimo-23 treated group.
• Figure 14 shows that a single dose of cMet/EGFR-25 at 3 mg/kg or 1 mg/kg had no significant tumor growth inhibition in HI 975 xenograft.
• Figure 15 shows that a single dose of cMet/EGFR-27 at 3mg/kg or lmg/kg, or a sigle dose of cMet-27 had no significant tumor growth inhibition in HCC827 xenograft.
• Figure 16 shows that no significant body weight loss was observed with a single dose of cMet/EGFR-ADC27 at 3 mg/kg or 1 mg/kg, or a single dose of cMet-ADC27 at 0.3 mg/kg during the study.
• a hyphen (-) designates the point to which a group is attached to the defined variable.
• a hyphen on the left side indicates connectivity to the left side structural component of formula (I) and hyphen on the right side indicates connectivity to the right side structural component of formula (I).
• L 2 is defined as -(CH 2 CH 2 0) m -
• L 1 is at the -CH 2 carbon
• the attachment to X is at the oxygen atom.
• N-hydroxysuccinimide (1.5 eq) was added, followed by EDC.HC1 (l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) (1.5 eq).
• EDC.HC1 l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
• the reaction mixture was stirred at room temperature for 1 h until most of the acid was consumed. The progress of the reaction was monitored by RP-HPLC.
• the mixture was then diluted with DCM and washed successively with citric acid (aq. 10%) and brine.
• the organic layer was dried and concentrated to dryness.
• the crude product was optionally purified by RP-HPLC or silica gel column chromatography.
• Compound 10 was converted to the corresponding activated ester following a general procedure prior to conjugating to an antibody.
• This example provides the results of EC50 assays (nM) of the designated drug conjugated antibodies measured in vitro in specified cells.
• the antibody used was an anti- HER2 IgG class of antibody.
• Seven breast cancer cell lines with various level of Her2 expression as indicated with plus or minus signs in the table below were plated in 96 well plate.
• the ADCs were serial diluted and added onto cells for treatment for 5 days.
• cell proliferation was measured by Promega's CellTitreGlo.
• EC50 (in nM) was determined as the concentration of 50% cell growth inhibition.
• the selection criteria for a successful compound included high efficacy, such as killing cell lines with high expression of the target receptor, with EC50 less than 3 nM.
• the successful candidate should have low toxicity and good therapeutic window, as determined by relatively low killing of the control cell line (MDA468) with low expression of the target receptor.
• Both ADCs 22 ( Figure 3) and 24 ( Figure 2) were selected as successful candidates with high efficacy and good therapeutic window.
• This example provides the results of EC50 assays (nM) of designated ADCs described herein measured in vitro in specified cells.
• the antibody used targets a receptor tyrosine kinase on cell surface.
• the ADCs were serial diluted and added onto cells for treatment for 5 days.
• cell proliferation was measured by Promega's CellTitreGlo.
• EC50 (in nM) was shown below and determined as the concentration of 50% cell growth inhibition.
• the selection criteria for a successful compound includes high efficacy, such as killing cell lines with high expression of the target receptor, with EC50 less than 3 nM.
• the successful candidate should have low toxicity and good therapeutic window, as determined by relatively low killing of the control cell lines (T-47D) with low expression of the target receptor.
• ADC 25 Figure 6) shows good cell killing efficacy in cell lines H1993, HCC827, SNU-5, and H292, but did not show efficacy in Hs746T, EBC-1 and U 87. It showed good therapeutic window since it did not kill the negative control cell line T-47 D.
• ADC 26 ( Figure 4) shows good cell killing activity in H1993 and SNu-5. However, it is not active in the other 6 cell lines.
• ADC 29 shows good cell killing efficacy in cell lines Hs746T, but did not show efficacy in EBC- 1 , U87, HCC827, HI 993 and T-47.
• HCC827, H292, H1975 cell lines were obtained from ATCC.
• the cells were cultured in RPMI 1640 IX (Corning 10-041-CV) medium with 10% FBS (Seradigm 1500-500) and penicillin streptomycin (Corning 30-002-CI) at 37 °C in a 5% carbon dioxide humidified environment. Cells were cultured for a period of 2 weeks and passaged 4 times before harvest. The cells were harvested with 0.25% trypsin (Corning 25- 050-CI).
• HCC827 cells Prior to injection, HCC827 cells were mixed in a 1: 1 ratio of HBSS (Hank's balanced salt solution; Ward's 470180-784) and matrigel (Corning 354234) mixture, and 7 million cells per 0.2 ml were injected subcutaneously into the upper right flank of each mouse.
• H292 cells were resuspended in HBSS, and 5 million cells per 0.2 ml were injected subcutaneously into the upper right flank of each mouse.
• H1975 cells were resuspended in HBSS, and 3 million cells per 0.2 ml were injected subcutaneously into the upper right flank of each mouse.
• mice Female Nu/Nu mice aged 5-7 weeks (Charles River) were used throughout these studies.
• mice Upon receipt, mice were housed 5 mice per cage in a room with a controlled environment. Rodent chow and water was provided ad libitum. Mice were acclimated to laboratory conditions for 72 hours before the start of dosing. The animals' health status was monitored during the acclimation period. Each cage was identified by group number and study number, and mice were identified individually by ear tags.
• Tumor growth was monitored by measurement of tumor width and length using a digital caliper starting day 5-7 after inoculation, and followed twice per week until tumor volume reached -100-250 mm .
• Tumor volume was measured twice weekly throughout the experimental period to determine TGI (tumor growth inhibition %).
• the body weight of each mouse was measured twice weekly by electric balance. Group average and standard deviation were calculated, and statistical analyses (one-way ANOVA with Dunnett's multiple comparison test; GraphPad Prism 6.0) was carried out. All treatment groups were compared with the PBS group. P ⁇ 0.05 was considered statistically significant.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Cell Biology (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Oncology (AREA)
• Toxicology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Botany (AREA)
• Biotechnology (AREA)
• Gastroenterology & Hepatology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pulmonology (AREA)
• Peptides Or Proteins (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=60421192

Family Applications (1)

Country Status (6)

Cited By (7)

Families Citing this family (11)

Citations (5)

Family Cites Families (8)

• 2017
  • 2017-05-31 EP EP17807392.0A patent/EP3471771A4/en not_active Withdrawn
  • 2017-05-31 WO PCT/US2017/035206 patent/WO2017210288A1/en not_active Ceased
  • 2017-05-31 CN CN202211405532.4A patent/CN115645544A/zh active Pending
  • 2017-05-31 US US15/609,858 patent/US11013816B2/en not_active Expired - Fee Related
  • 2017-05-31 CN CN201780033085.5A patent/CN109195631B/zh active Active
  • 2017-05-31 JP JP2018562186A patent/JP7103953B2/ja not_active Expired - Fee Related
  • 2017-05-31 CA CA3025931A patent/CA3025931A1/en active Pending
• 2021
  • 2021-04-26 US US17/240,700 patent/US20210260211A1/en not_active Abandoned
  • 2021-09-02 JP JP2021143103A patent/JP7403507B2/ja active Active

Patent Citations (5)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events